Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol ... Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.036663 | 3.98510869565 | 0.92 | 1.05 | 0.878 | 103711 | 0.97386294 | CS |
| 4 | -0.153337 | -13.8141441441 | 1.11 | 1.17 | 0.878 | 141801 | 1.05736133 | CS |
| 12 | 0.046663 | 5.1278021978 | 0.91 | 1.56 | 0.81 | 201511 | 1.12514201 | CS |
| 26 | -0.233337 | -19.6081512605 | 1.19 | 1.56 | 0.81 | 201754 | 1.10709153 | CS |
| 52 | -0.233337 | -19.6081512605 | 1.19 | 1.56 | 0.81 | 201754 | 1.10709153 | CS |
| 156 | -0.233337 | -19.6081512605 | 1.19 | 1.56 | 0.81 | 201754 | 1.10709153 | CS |
| 260 | -0.233337 | -19.6081512605 | 1.19 | 1.56 | 0.81 | 201754 | 1.10709153 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
